30 results
424B3
ELVN
Enliven Therapeutics Inc
30 Apr 24
Prospectus supplement
4:16pm
”) gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (“CML”). Although the approval of BCR-ABL tyrosine kinase inhibitors
8-K
ELVN
Enliven Therapeutics Inc
11 Apr 24
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
8:02am
a press release announcing initial proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid
8-K
EX-99.1
ELVN
Enliven Therapeutics Inc
11 Apr 24
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
8:02am
Exhibit 99.1
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia … announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who
8-K
EX-99.1
ELVN
Enliven Therapeutics Inc
19 Mar 24
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
8:46am
, to discuss initial proof of concept data from a Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML)
BOULDER, Colo., March 19
8-K
EX-99.1
wjd5sm2kqx xhsuffx5
14 Mar 24
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
4:10pm
8-K
EX-99.1
1woxlz5vwm6ofw8
9 Nov 23
Enliven Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:10pm
8-K
EX-99.1
qvwwkskr95o95id6 3g
10 Aug 23
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
4:10pm
424B5
ro9ae
6 Jul 23
Prospectus supplement for primary offering
4:06pm
8-K
EX-99.1
a0n7g 7ocb8fa
11 May 23
Enliven Therapeutics Highlights Business Achievements and Reports First Quarter 2023 Financial Results
4:11pm
S-4/A
rx01cq
19 Dec 22
Registration of securities issued in business combination transactions (amended)
9:01am
S-4
cw97jhw
10 Nov 22
Registration of securities issued in business combination transactions
4:23pm
425
nw5m 5qoptb
13 Oct 22
Business combination disclosure
9:06pm
8-K
EX-99.1
y056qk bimuy5tc5o
13 Oct 22
Enliven Therapeutics, Inc. and Imara Inc. Announce Definitive Merger Agreement
9:04pm
8-K
EX-99.2
gvjeaq9e 54a0
13 Oct 22
Enliven Therapeutics and Imara Announce Merger Agreement
4:43pm